Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUIDANCE maintenance durvalumab + olaparib in HRD-positive extensive-stage SCLC
2024-512373-27-00Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Sep 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and olaparib in small cell lung cancer (SCLC), sponsored by University of Cologne. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
durvalumabolaparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-512373-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512373-27-00.